Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.58 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028831 | 1.00 | KCNH2 (0.58) | KCNH2CARM1PRMT6PTGS1SLC6A2 | |
| SCHEMBL2363925 | 0.88 | KCNH2 (0.72) | KCNH2PTGS1SLC6A2SLC6A4SCN9A | |
| SCHEMBL2363928 | 0.88 | KCNH2 (0.72) | KCNH2PTGS1SLC6A2SLC6A4SCN9A | |
| SCHEMBL3038267 | 0.86 | KCNH2 (0.55) | KCNH2PTGS1SLC6A2SLC6A4CHRM4 | |
| SCHEMBL3038264 | 0.86 | KCNH2 (0.55) | KCNH2PTGS1SLC6A2SLC6A4CHRM4 | |
| SCHEMBL3664769 | 0.85 | KCNH2 (0.67) | KCNH2PTGS1SLC6A2SLC6A4SCN9A | |
| SCHEMBL3664766 | 0.85 | KCNH2 (0.67) | KCNH2PTGS1SLC6A2SLC6A4SCN9A | |
| SCHEMBL27801411 | 0.81 | CARM1 (0.52) | KCNH2CARM1PRMT6PTGS1SLC6A2 | |
| SCHEMBL2095960 | 0.81 | CARM1 (0.58) | KCNH2CARM1PRMT6SCN9ASCN4A | |
| SCHEMBL3028014 | 0.81 | CARM1 (0.51) | KCNH2CARM1PRMT6PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552188-B2 | Epoxy compound and method for manufacturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | claimed |
| US-20130072683-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | claimed |
| EP-2144899-B1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2011-12-07 | — | — | EP | claimed |
| US-20100217005-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | claimed |
| US-8552188-B2 | Epoxy compound and method for manufacturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20130072683-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-8344148-B2 | Epoxy compound and method for manufacturing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-2144899-B1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2011-12-07 | — | — | EP | disclosed |
| US-20100217005-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2144899-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008140090-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072683-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | SQLE, CYP2E1, CYP1A1 | KCNH2 1413/4885CARM1 359/4885PRMT6 1134/4885 |
| US-20100217005-A1 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME | SQLE, CYP2E1, CYP1A1 | KCNH2 1327/4885CARM1 409/4885PRMT6 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.